Proactive Investors - Run By Investors For Investors

Ellex Medical Lasers has support for its macular degeneration treatment

Ellex Medical Lasers has support for its macular degeneration treatment

Ellex Medical Lasers (ASX:ELX) has announced additional scientific research validating the method of action of the company’s proprietary Retinal Rejuvenation Therapy (2RT) for the treatment of early age-related macular degeneration.

Research found that directly following treatment by 2RT of the targeted retinal pigment epithelium (RPE) cells, the surrounding, surviving cells grew into the vacated spaces and stimulated expression of a range of protein factors, triggering a regenerative effect on nearby RPE cells.

This confirmed the positive cellular response induced by 2RT, validating its previously postulated method of action.

It offers the potential for 2RT to emerge as a platform technology that could provide additional, alternative therapeutic applications.

The research is expected to be published in a peer-review publication during the 2016 financial year.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full ELX profile View Profile

Ellex Medical Lasers Timeline

November 30 2016

Related Articles

myLotus testing kit
October 31 2018
The launch at the Fertility Show in London at the start of November is the first step in a switch in focus brought about by new executive chairman Matthew Walls
scientist looking through microscope
April 12 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
CBD oil
November 16 2018
The company’s technology creates nano-scale emulsion mixtures that allow fluids to mix that normally don’t mix, such as CBD oil and water

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use